RedHill Biopharma (RDHL) Common Equity (2022 - 2024)

RedHill Biopharma (RDHL) has disclosed Common Equity for 3 consecutive years, with -$4.7 million as the latest value for Q4 2024.

  • Quarterly Common Equity fell 326.34% to -$4.7 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was -$4.7 million through Dec 2024, down 326.34% year-over-year, with the annual reading at -$4.7 million for FY2024, 326.34% down from the prior year.
  • Common Equity for Q4 2024 was -$4.7 million at RedHill Biopharma, down from $2.1 million in the prior quarter.
  • The five-year high for Common Equity was $2.1 million in Q4 2023, with the low at -$48.4 million in Q4 2022.
  • Average Common Equity over 3 years is -$17.0 million, with a median of -$4.7 million recorded in 2024.
  • The sharpest move saw Common Equity soared 104.27% in 2023, then crashed 326.34% in 2024.
  • Over 3 years, Common Equity stood at -$48.4 million in 2022, then soared by 104.27% to $2.1 million in 2023, then crashed by 326.34% to -$4.7 million in 2024.
  • According to Business Quant data, Common Equity over the past three periods came in at -$4.7 million, $2.1 million, and -$48.4 million for Q4 2024, Q4 2023, and Q4 2022 respectively.